Skip to main content

Advertisement

Table 1 Odds ratios for having the metabolic syndrome in patients receiving methotrexate monotherapy compared with those not on methotrexate

From: Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome - authors' response

  NCEP 2004 NCEP 2001
  OR (95% CI) OR (95% CI)
  n = 62 n = 62
Crude 0.415 (0.21-0.82), 0.368 (0.19-0.73),
  P = 0.011 P = 0.004
Model a 0.421 (0.21-0.84), 0.373 (0.19-0.75),
  P = 0.014 P = 0.006
Model b 0.468 (0.23-0.99), 0.408 (0.19-0.84),
  P = 0.038 P = 0.015
  1. Crude: Unadjusted model. Model a: adjusted for age and gender. Model b: adjusted for age, gender, disease duration, erythrocyte sedimentation rate, and health assessment questionnaire score. CI, confidence interval; NCEP, National Cholesterol Education Program; OR, odds ratio.